NCT04809103View on ClinicalTrials.gov

Intratumoral Cisplatin for Resectable NSCLC

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

September 1, 2024

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

cis-diamminedichloroplatinum

Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC

Trial Locations (1)

05405

RECRUITING

University of Vermont, Burlington

Sponsors

Collaborators (1)

Johnson & Johnson
All Listed Sponsors
collaborator

Johnson & Johnson

INDUSTRY

lead

University of Vermont

OTHER